21 July 2022: Clinical Research
Serum T Cell Immunoglobulin Mucin 3 Predicts Worse Prognosis in Hepatocellular Carcinoma Patients Undergoing Transcatheter Arterial Chemoembolization
Jun Li BCDE , Jing Wang ABCEF*DOI: 10.12659/MSM.935326
Med Sci Monit 2022; 28:e935326
Figure 1 Serum Tim-3 distribution and correlation with serum AFP level. (A) Distribution of serum Tim-3 in healthy controls, resectable HCC patients, and unresectable HCC patients receiving TACE treatment. (B) Correlation between serum Tim-3 and AFP in the training set. (C) Correlation between serum Tim-3 and AFP in the validation set. AFP – alpha-fetoprotein; HC – healthy controls; HCC – hepatocellular carcinoma; TACE – transcatheter arterial chemoembolization; Tim-3 – T cell immunoglobulin and mucin domain 3.